We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Read MoreHide Full Article
Key Takeaways
Bristol Myers Squibb's growth portfolio rose 13%, reaching 56% of first-half 2026 revenues.
Opdivo Qvantig, Reblozyl, Breyanzi and Camzyos are driving gains across key franchises.
Sotyktu, Cobenfy and Zenbexus add new growth opportunities through approvals and pipeline development.
Bristol Myers Squibb (BMY - Free Report) is undergoing a meaningful shift in its revenue mix, with its growth portfolio taking on a larger role and increasingly offsetting the pressure from mature products facing generic competition.
The growth portfolio — comprising Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyktu, Krazati and Cobenfy — is becoming increasingly important to the company’s top-line performance.
Sales from these products increased 13% in the first half of 2026, raising their contribution to 56% of total revenues from 51.8% in the first half of 2025. The expanding contribution of newer brands is strengthening the company’s revenue base and providing greater support for long-term growth.
Several products were key contributors to this performance, including Reblozyl, Breyanzi, Opdualag, Opdivo Qvantig, Camzyos and Cobenfy.
Opdivo Qvantig, the subcutaneous formulation of Opdivo (nivolumab and hyaluronidase-nvhy), has gained strong traction across all approved tumor types in the United States. The product is now generating more than $1 billion in annualized revenues, helping offset the decline in intravenous Opdivo sales as patients transition to the subcutaneous formulation.
Opdualag continues to benefit from strong global demand and its established position as a first-line standard of care for melanoma in the United States.
Reblozyl is another important growth contributor, supported by solid uptake in first-line myelodysplastic syndrome-associated anemia, sustained demand in the second-line setting and increasing penetration among first-line RS-negative patients.
Breyanzi’s growing adoption underscores the drug’s expanding role within BMY’s hematology franchise.
Cardiovascular drug Camzyos continues to gain traction, aided by promotional efforts, a growing base of new patient prescribers and increasing penetration in the community setting. An expanding indication base could provide additional growth opportunities.
Sotyktu is strengthening BMY’s immunology franchise following its approval in psoriatic arthritis (PsA), which expands the drug’s commercial opportunity beyond plaque psoriasis. The company recently reported positive two-year results from the phase III POETYK PsA-2 study and its open-label extension, providing evidence of sustained efficacy and a consistent safety profile with longer-term treatment.
Further upside could come from ongoing phase III programs in systemic lupus erythematosus and Sjögren’s disease. Successful development in these indications could significantly broaden Sotyktu’s addressable market.
Cobenfy provides another source of long-term growth potential. The schizophrenia drug’s early launch momentum, together with potential future label expansions, could establish it as an increasingly meaningful contributor to the portfolio.
BMY is also expanding its multiple myeloma franchise. The FDA recently granted accelerated approval to iberdomide, in combination with daratumumab and hyaluronidase-fihj and dexamethasone under the brand name Zenbexus, for adults with multiple myeloma who have received at least one prior line of therapy. Zenbexus is the first FDA-approved cereblon E3 ligase modulator, adding a novel protein-degradation approach to BMY’s oncology portfolio.
Despite this progress, the portfolio transition remains important to monitor. Legacy products, including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, accounted for 44% of revenues and face varying degrees of pressure from loss of exclusivity and generic competition.
Nevertheless, BMY is actively reshaping its portfolio through new approvals, label expansions and pipeline development. The increasing contribution from newer products is helping offset revenue losses from mature-product erosion and providing a foundation for sustained long-term growth.
BMY’s Competition in Oncology Space
Oncology remains a core therapeutic area for BMY, with the company leveraging its expertise in immuno-oncology and hematology to develop and commercialize medicines across a broad range of cancers. BMY continues to invest in next-generation therapies and expand its oncology portfolio through internal development, strategic collaborations and acquisitions.
The company competes with major pharmaceutical players, including Merck (MRK - Free Report) and Pfizer (PFE - Free Report) , across several oncology markets.
Merck remains a formidable competitor in immuno-oncology, led by its blockbuster Keytruda (pembrolizumab). The drug is approved across numerous cancer indications and remains a major contributor to Merck’s pharmaceutical business. Merck is pursuing multiple strategies, including new indications and combination approaches, to extend Keytruda’s growth trajectory.
Pfizer also maintains a broad oncology franchise spanning antibody-drug conjugates (ADCs), small molecules, bispecific antibodies and other immune-oncology biologics. Its portfolio covers several major cancer types, including breast, gastrointestinal, genitourinary, hematologic and thoracic cancers. Pfizer significantly strengthened its oncology capabilities through the acquisition of Seagen, adding a leading ADC platform and a portfolio of targeted cancer therapies.
Pfizer has further expanded its oncology pipeline through its collaboration with 3SBio for SSGJ-707, an investigational bispecific antibody targeting PD-1 and VEGF.
BMY’s Price Performance, Valuation & Estimates
Shares of Bristol Myers have gained 13.4% year to date compared with the industry’s growth of 8.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, its shares currently trade at 9.28X forward earnings, higher than its mean of 8.72X but lower than the large-cap pharma industry’s 18.23X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.91 from $6.34 in the past 60 days, while that for 2027 EPS has improved to $6.46 from $6.12 in the same time frame.
View the Zacks #1 Rank List
Image: Shutterstock
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Key Takeaways
Bristol Myers Squibb (BMY - Free Report) is undergoing a meaningful shift in its revenue mix, with its growth portfolio taking on a larger role and increasingly offsetting the pressure from mature products facing generic competition.
The growth portfolio — comprising Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyktu, Krazati and Cobenfy — is becoming increasingly important to the company’s top-line performance.
Sales from these products increased 13% in the first half of 2026, raising their contribution to 56% of total revenues from 51.8% in the first half of 2025. The expanding contribution of newer brands is strengthening the company’s revenue base and providing greater support for long-term growth.
Several products were key contributors to this performance, including Reblozyl, Breyanzi, Opdualag, Opdivo Qvantig, Camzyos and Cobenfy.
Opdivo Qvantig, the subcutaneous formulation of Opdivo (nivolumab and hyaluronidase-nvhy), has gained strong traction across all approved tumor types in the United States. The product is now generating more than $1 billion in annualized revenues, helping offset the decline in intravenous Opdivo sales as patients transition to the subcutaneous formulation.
Opdualag continues to benefit from strong global demand and its established position as a first-line standard of care for melanoma in the United States.
Reblozyl is another important growth contributor, supported by solid uptake in first-line myelodysplastic syndrome-associated anemia, sustained demand in the second-line setting and increasing penetration among first-line RS-negative patients.
Breyanzi’s growing adoption underscores the drug’s expanding role within BMY’s hematology franchise.
Cardiovascular drug Camzyos continues to gain traction, aided by promotional efforts, a growing base of new patient prescribers and increasing penetration in the community setting. An expanding indication base could provide additional growth opportunities.
Sotyktu is strengthening BMY’s immunology franchise following its approval in psoriatic arthritis (PsA), which expands the drug’s commercial opportunity beyond plaque psoriasis. The company recently reported positive two-year results from the phase III POETYK PsA-2 study and its open-label extension, providing evidence of sustained efficacy and a consistent safety profile with longer-term treatment.
Further upside could come from ongoing phase III programs in systemic lupus erythematosus and Sjögren’s disease. Successful development in these indications could significantly broaden Sotyktu’s addressable market.
Cobenfy provides another source of long-term growth potential. The schizophrenia drug’s early launch momentum, together with potential future label expansions, could establish it as an increasingly meaningful contributor to the portfolio.
BMY is also expanding its multiple myeloma franchise. The FDA recently granted accelerated approval to iberdomide, in combination with daratumumab and hyaluronidase-fihj and dexamethasone under the brand name Zenbexus, for adults with multiple myeloma who have received at least one prior line of therapy. Zenbexus is the first FDA-approved cereblon E3 ligase modulator, adding a novel protein-degradation approach to BMY’s oncology portfolio.
Despite this progress, the portfolio transition remains important to monitor. Legacy products, including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, accounted for 44% of revenues and face varying degrees of pressure from loss of exclusivity and generic competition.
Nevertheless, BMY is actively reshaping its portfolio through new approvals, label expansions and pipeline development. The increasing contribution from newer products is helping offset revenue losses from mature-product erosion and providing a foundation for sustained long-term growth.
BMY’s Competition in Oncology Space
Oncology remains a core therapeutic area for BMY, with the company leveraging its expertise in immuno-oncology and hematology to develop and commercialize medicines across a broad range of cancers. BMY continues to invest in next-generation therapies and expand its oncology portfolio through internal development, strategic collaborations and acquisitions.
The company competes with major pharmaceutical players, including Merck (MRK - Free Report) and Pfizer (PFE - Free Report) , across several oncology markets.
Merck remains a formidable competitor in immuno-oncology, led by its blockbuster Keytruda (pembrolizumab). The drug is approved across numerous cancer indications and remains a major contributor to Merck’s pharmaceutical business. Merck is pursuing multiple strategies, including new indications and combination approaches, to extend Keytruda’s growth trajectory.
Pfizer also maintains a broad oncology franchise spanning antibody-drug conjugates (ADCs), small molecules, bispecific antibodies and other immune-oncology biologics. Its portfolio covers several major cancer types, including breast, gastrointestinal, genitourinary, hematologic and thoracic cancers. Pfizer significantly strengthened its oncology capabilities through the acquisition of Seagen, adding a leading ADC platform and a portfolio of targeted cancer therapies.
Pfizer has further expanded its oncology pipeline through its collaboration with 3SBio for SSGJ-707, an investigational bispecific antibody targeting PD-1 and VEGF.
BMY’s Price Performance, Valuation & Estimates
Shares of Bristol Myers have gained 13.4% year to date compared with the industry’s growth of 8.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, its shares currently trade at 9.28X forward earnings, higher than its mean of 8.72X but lower than the large-cap pharma industry’s 18.23X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.91 from $6.34 in the past 60 days, while that for 2027 EPS has improved to $6.46 from $6.12 in the same time frame.
Image Source: Zacks Investment Research
BMY currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.